Global pharmaceutical company Mylan, Inc. (MYL) Tuesday said the Court of Appeals for the Federal Circuit has ruled in favor of Mylan Specialty L.P., f/k/a Dey Pharma, L.P. and has reversed the District Court's decision invalidating five of Mylan's patents related to Perforomist.
Commenting on the development, Mylan CEO Heather Bresch said, "We are pleased with the Court's decision as it confirms our original belief in the strength and validity of the intellectual property protecting Perforomist, as well as our combination product for the treatment of Chronic Obstructive Pulmonary Disease, currently in development. We believe this decision by the Court only further supports the strength of our Specialty franchise."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.